Global Fallout: How a Regional India-Pakistan Conflict Could Trigger International Cyber Disruptions and Propaganda Wars
Descartes MacroPoint™ FraudGuard 2.0 Provides Transportation Industry with Next-Generation Solution for Freight Fraud Defense
Huatai Foundation Supports NbS Summer School, Convening Global Youth to Tackle Ecological Conservation
Progress towards potassium-ion batteries
15 World Toppers and Near-Perfect Scorers for GIIS Singapore in IBDP 2025 Exams
— Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed…
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and…
Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and…
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib…
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral…
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose…
AFM13 in combination with NK cells shows very high overall and complete response rates in…
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in…
Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium,…
With nearly four years of study follow-up, all-oral, fixed-duration IMBRUVICA® (ibrutinib) + venetoclax reduced the…
Results from the pivotal MonumenTAL-1 study, including first results from the Phase 2 portion, featured…
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this…
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML ––…
– A total of 17 pediatric patients were treated with STRO-002 on a compassionate use…
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts UTRECHT,…
-Participants with SR-aGVHD disease achieved an ORR of 67% and CR of 17% as measured…
Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-making…
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel…
ONTARIO, CA, Dec 10, 2022 – (ACN Newswire) – The founders of i-Create LLC are…
Digital marketing e-commerce consultancy ScottHall.co has released a Best Practices guide that offers entrepreneurs and…